Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.


Clinical Trial Description

RSV is an important cause of serious respiratory infections in adults aged 60 years and older, immunocompromised individuals, and those with underlying chronic cardiopulmonary conditions. The current study assess the safety and immunogenicity of the RSV vaccine in adults 18 to 59 years of age, including those who are at risk for severe RSV disease. The study comprises screening (pre-vaccination) and vaccination for each participant on Day 1, and a 6- month safety and immunogenicity follow-up period. The study duration will be up to 6 months per participant. Assessments like immunogenicity (such as humoral and cellular immune responses), safety (such as monitoring of AEs, physical examinations, and vital signs) and reactogenicity will be performed in this study. ;


Study Design


Related Conditions & MeSH terms

  • Infections
  • Respiratory Syncytial Virus Infections

NCT number NCT05070546
Study type Interventional
Source Janssen Vaccines & Prevention B.V.
Contact Study Contact
Phone 844-434-4210
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date October 4, 2021
Completion date June 14, 2022